Benjamin Edwards Inc. Has $1.17 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Benjamin Edwards Inc. reduced its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 47.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,648 shares of the biopharmaceutical company's stock after selling 1,489 shares during the quarter. Benjamin Edwards Inc.'s holdings in Regeneron Pharmaceuticals were worth $1,174,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Willner & Heller LLC boosted its position in shares of Regeneron Pharmaceuticals by 3.9% during the fourth quarter. Willner & Heller LLC now owns 399 shares of the biopharmaceutical company's stock worth $284,000 after buying an additional 15 shares during the period. OLD Second National Bank of Aurora boosted its position in Regeneron Pharmaceuticals by 0.5% during the 4th quarter. OLD Second National Bank of Aurora now owns 2,843 shares of the biopharmaceutical company's stock worth $2,025,000 after acquiring an additional 15 shares during the last quarter. Rakuten Securities Inc. grew its stake in shares of Regeneron Pharmaceuticals by 62.5% during the 4th quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after acquiring an additional 15 shares in the last quarter. TD Private Client Wealth LLC raised its holdings in shares of Regeneron Pharmaceuticals by 9.6% in the fourth quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company's stock valued at $122,000 after purchasing an additional 15 shares during the last quarter. Finally, Manchester Capital Management LLC lifted its position in shares of Regeneron Pharmaceuticals by 12.6% in the fourth quarter. Manchester Capital Management LLC now owns 161 shares of the biopharmaceutical company's stock worth $115,000 after purchasing an additional 18 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Wells Fargo & Company lowered their price target on shares of Regeneron Pharmaceuticals from $750.00 to $700.00 and set an "overweight" rating on the stock in a research note on Wednesday, April 30th. TD Cowen reduced their price target on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating for the company in a research report on Tuesday, February 4th. BMO Capital Markets lowered their price target on Regeneron Pharmaceuticals from $865.00 to $800.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 30th. Cantor Fitzgerald started coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $695.00 target price for the company. Finally, Piper Sandler dropped their price target on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating on the stock in a research report on Monday, January 27th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, eighteen have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $892.60.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $560.70 on Thursday. The business has a fifty day moving average price of $618.78 and a two-hundred day moving average price of $702.67. The stock has a market capitalization of $61.30 billion, a PE ratio of 14.65, a P/E/G ratio of 2.34 and a beta of 0.43. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $525.99 and a fifty-two week high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 EPS for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). The company had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm's revenue for the quarter was down 3.7% compared to the same quarter last year. During the same period last year, the firm earned $9.55 EPS. As a group, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Tuesday, May 20th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.63%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 8.96%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.